We serve Chemical Name:Cefoselis CAS:122841-10-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Cefoselis
CAS.NO:122841-10-5
Synonyms:5-Amino-2-{[(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-(2-hydroxyethyl)-1H-pyrazol-2-ium hydrogen sulfate;FK 037 {Sulfate};Wincef
Molecular Formula:C19H22N8O6S2
Molecular Weight:522.56
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:341.62000
Exact Mass:
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-Amino-2-{[(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-(2-hydroxyethyl)-1H-pyrazol-2-ium hydrogen sulfate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Wincef physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,FK 037 {Sulfate} Use and application,Wincef technical grade,usp/ep/jp grade.
Related News: The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application. Cefoselis manufacturer This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body. Cefoselis supplier This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body. Cefoselis vendor The technology supports breakthroughs in medical research and is widely used by major global pharmaceutical companies to advance drug discovery & development and provide data to support regulatory submissions. Cefoselis factory A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.
